Vertex Pharmaceuticals/$VRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Ticker
$VRTX
Sector
Primary listing
Employees
6,100
Headquarters
Website
VRTX Metrics
BasicAdvanced
$100B
27.62
$14.07
0.44
-
Price and volume
Market cap
$100B
Beta
0.44
52-week high
$519.68
52-week low
$362.50
Average daily volume
2.2M
Financial strength
Current ratio
2.52
Quick ratio
2
Long term debt to equity
8.893
Total debt to equity
8.893
Interest coverage (TTM)
272.16%
Profitability
EBITDA (TTM)
4,589.3
Gross margin (TTM)
52.48%
Net profit margin (TTM)
31.86%
Operating margin (TTM)
40.52%
Effective tax rate (TTM)
16.84%
Revenue per employee (TTM)
$1,870,000
Management effectiveness
Return on assets (TTM)
12.50%
Return on equity (TTM)
22.77%
Valuation
Price to earnings (TTM)
27.615
Price to revenue (TTM)
8.754
Price to book
5.8
Price to tangible book (TTM)
6.36
Price to free cash flow (TTM)
28.561
Free cash flow yield (TTM)
3.50%
Free cash flow per share (TTM)
13.604
Growth
Revenue change (TTM)
10.46%
Earnings per share change (TTM)
-838.64%
3-year revenue growth (CAGR)
11.00%
10-year revenue growth (CAGR)
33.65%
3-year earnings per share growth (CAGR)
4.38%
10-year earnings per share growth (CAGR)
16.42%
What the Analysts think about VRTX
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
Bulls say / Bears say
Vertex reported Q2 2025 revenue of $2.96 billion, up 12% year-on-year, and adjusted EPS of $4.52, both beating Wall Street estimates on sustained demand for its cystic fibrosis therapies (Reuters)
The European Union’s approval of Alyftrek, a once-daily cystic fibrosis treatment, strengthens Vertex’s global CF franchise and extends its standard-of-care leadership (Reuters)
Management maintained full-year 2025 revenue guidance of $11.85–12.00 billion despite a late-stage trial setback, reflecting confidence in its core CF business and minimal impact from external headwinds (Reuters)
Vertex discontinued development of its experimental non-opioid painkiller VX-993 after a mid-stage trial failed to show statistical efficacy, sending shares down about 12% and raising questions on its pain portfolio diversification (Reuters)
The company halted plans to study Journavx for nerve pain in the lower back and legs after FDA discussions, undermining expectations for non-CF revenue growth and dampening investor sentiment (Reuters)
Journavx has accrued only 79,763 prescriptions since launch, a slower uptake than analysts anticipated, putting pressure on its contribution to offset reliance on cystic fibrosis revenues (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
VRTX Financial Performance
Revenues and expenses
VRTX Earnings Performance
Company profitability
VRTX News
AllArticlesVideos
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
Business Wire4 hours ago
Vertex to Participate in Upcoming September Investor Conferences
Business Wire3 weeks ago
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results
Benzinga1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $100B as of September 11, 2025.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 27.62 as of September 11, 2025.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of September 11, 2025.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.